It has been proven that the activity of chronic inflammation is one of the leading factors in the development of comorbid pathology in endstage renal disease (ESRD) patients. However, the clinical significance of anti-inflammatory mediators in this patient population has been studied quite limited. Study the role of IL-10 in the pathogenesis of comorbidity, due to its inherent properties, causes great interest.
Aim: The aim of the study was to determine the serum profile of IL-10 and to investigate the specifics of mortality, comorbid status and frequency of comorbid conditions in ESRD patients treated with hemodialysis (HD) depending on the serum concentrations of this cytokine.
Materials and methods: The cohort prospective study included 188 ESRD patients treated with hemodialysis during 2012-2019. All reported comorbidities, their frequency and dynamics of changes, modified index of polymorbidity (MIP), deaths were analyzed depending on IL-10 serum levels. Serum cytokine levels were determined by ELISA. Statistical analysis was performed by using "MedCalc", version 19.2.
Results: Serum IL-10 levels were significantly lower in HD patients with 5 or more comorbidities. IL-10 levels ≤28,3 pg/mL have a strong negative effect on the clinical prognosis in ESRD patients treated with HD. In particular, contribute to a significant increase, during the observation period, the number of comorbidities and the frequency of CVD, both compared with the beginning of the study (p<0,001) and in patients with IL-10>28,3 pg/mL (p=0,003). The proportion of deceased patients with IL-10 levels ≤28,3 pg/mL is more than 50 % higher than that of patients with IL-10 levels >28,3 pg/mL (p=0,024).
Conclusions: Serum IL-10 level ≤28,3 pg/mL is an independent predictor of increased MIP, comorbid cardiovascular disease frequency and overall mortality in patients treated with HD.
Keywords: cardiovascular disease; comorbidity; end-stage renal disease; hemodialysis; interleukin-10.
© 2021 MEDPRESS.